Bank of America just raised its EUR/USD forecast
22nd Century Group, Inc. (NASDAQ:XXII) issued its earnings release for the quarter ended June 30, 2025, according to a statement provided in a Securities and Exchange Commission filing on Thursday. The company reported that a copy of the earnings release was furnished as Exhibit 99.1 to the report. The announcement comes as InvestingPro data shows the company generated $23.87 million in revenue over the last twelve months, though facing profitability challenges with negative EBITDA of $11 million.
No additional financial details or operating results were disclosed in the SEC filing itself. The filing was signed by Chief Financial Officer Daniel A. Otto. According to InvestingPro analysis, analysts expect both sales and net income growth this year, despite current challenges. InvestingPro subscribers have access to 20+ additional insights and detailed financial metrics in the comprehensive Pro Research Report for XXII, helping investors make more informed decisions.
This article is based on a press release statement contained in the company’s SEC filing. The company’s next earnings release is scheduled for August 14, 2025.
In other recent news, 22nd Century Group has been actively expanding its presence in the tobacco industry. The company announced new partnerships to increase the availability of its VLN® reduced nicotine content cigarettes, which contain 95% less nicotine than conventional products. These partnerships, including Smoker Friendly VLN® and Pinnacle VLN®, align with the FDA’s proposed Tobacco Product Standard that seeks to limit nicotine content in cigarettes. Additionally, 22nd Century Group plans to develop a 100mm version of its VLN® cigarettes, with an FDA submission expected in the fourth quarter of 2025, aiming to capture a significant portion of the U.S. cigarette market.
The company also received approval from its stockholders to amend its Articles of Incorporation, increasing the number of authorized shares from 250 million to 500 million. This amendment has been filed and is now effective. Furthermore, 22nd Century Group issued a statement supporting the FDA’s proposed nicotine standard, highlighting backing from the American Academy of Family Physicians. These developments reflect the company’s strategic moves to adapt to regulatory changes and expand its product offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.